BioAssay Works LLC (BAW), a leading developer and manufacturer of lateral flow assays and reagents, is pleased to announce the appointment of Dr. Doğuş Işık and Dr. Olivier Côté as its new Chief Executive Officers.

Doğuş brings extensive experience in scalable nanotechnology solutions to the role, with a proven track record of achievement in academia and multinational organizations. Olivier, who has been serving as BAW’s Vice President of Research and Development, steps up to co-lead the company, bringing deep expertise in innovation and product development.

“We are delighted to welcome Doğuş and to see Olivier expand his leadership role as co-CEOs,” said Stephen Mefferd, BAW’s co-founder. “Their combined industry knowledge, technical expertise, and leadership skills will be instrumental in driving BAW’s continued growth and innovation.”

Doğuş commented, “I am honored to join BAW and excited to work with the talented team already in place. I look forward to driving the next generation of BAW technology and growing our list of satisfied customers.”

Olivier added, “I am excited to step into this expanded role and to continue shaping the future of BAW’s cutting-edge lateral flow solutions. With the new leadership and our dedicated team, we are poised for incredible advancements.”

Learn more about Doğuş and Olivier here.